CD274 and neoplasm: PLX51107 also enhanced anti–PD-L1 therapy in the LLC model, where the combination treatment again most strongly inhibited tumor growth paired with a reduction in total splenic MDSCs in the combination arm compared with anti–PD-L1 (Figure 7A and Supplemental Figure 17A; P < 0.01).